FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical industry and represents rectal polycomplex gel for treatment of ulcerative colitis, Crohn's disease, fistulas and complications, caused by these diseases characterized by that it contains metronidazole, timogen, carbopol, propylene glycol, disodium EDTA, propyl parahydroxybenzoate, methyl parahydroxybenzoate, sodium hydroxide and water, wherein ingredients of gel are taken in certain proportions, g/150 g.
EFFECT: invention provides higher clinical effectiveness in treatment of non-infectious inflammatory diseases of intestinal-digestive tract, reduced length of treatment.
1 cl, 3 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MELATONIN AGENT FOR TREATING INFLAMMATORY BOWEL DISEASES IN THE FORM OF RECTAL SUPPOSITORIES | 2023 |
|
RU2819721C1 |
| AGENT WITH VITAMIN D3 FOR TREATING ULCERATIVE COLITIS IN THE FORM OF RECTAL SUPPOSITORIES | 2019 |
|
RU2709209C1 |
| RECTAL SUPPOSITORIES, HAVING ANTI-INFLAMMATORY, ANTIOXIDANT, IMMUNOSTIMULATING ACTION, CONTAINING RHIZOMES WITH COMMON TURMERIC ROOTS | 2020 |
|
RU2743427C1 |
| PREPARATION CONTAINING DIAMINOTRIFLUOROMETHYL PYRIDINE DERIVATIVE FOR TREATING AND PREVENTING ALIMENTARY DISEASES | 2001 |
|
RU2266114C2 |
| PREPARATION FOR TREATMENT OF NONINFECTIOUS INFLAMMATORY INTESTINE DISEASES | 2005 |
|
RU2297835C1 |
| KOBITOLIMOD FOR USE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2018 |
|
RU2766356C2 |
| METHOD FOR TREATING INFLAMMATORY DISEASES OF TERMINAL COLON | 2022 |
|
RU2807235C1 |
| METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2009 |
|
RU2394571C1 |
| AGENT FOR CELL METABOLIC PROCESS REGULATION | 2011 |
|
RU2487720C1 |
| COMPOSITIONS AND METHODS OF THE TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE | 2019 |
|
RU2799556C2 |
